Locally advanced breast cancer()

por Aebi, Stefan, Karlsson, Per, Wapnir, Irene L.
Publicado 2021

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

por Ernst, Tina, Aebi, Stefan, Zander, Andrea, Zander, Thilo
Publicado 2022

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

por Amstutz, Ursula, Farese, Simone, Aebi, Stefan, Largiadèr, Carlo R
Publicado 2008

Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq

por Bustamante Eduardo, Mariana, Keller, Irene, Schuster, Nathalie, Aebi, Stefan, Jaggi, Rolf
Publicado 2023

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland

por Begré, Ursina B. M., Jörger, Markus, Aebi, Stefan, Amstutz, Ursula, Largiadèr, Carlo R.
Publicado 2022

Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases

por Bustamante Eduardo, Mariana, Popovici, Vlad, Imboden, Sara, Aebi, Stefan, Ballabio, Nadja, Altermatt, Hans Jörg, Günthert, Andreas, Jaggi, Rolf
Publicado 2019

Expression profiling with RNA from formalin-fixed, paraffin-embedded material

por Oberli, Andrea, Popovici, Vlad, Delorenzi, Mauro, Baltzer, Anna, Antonov, Janine, Matthey, Sybille, Aebi, Stefan, Altermatt, Hans Jörg, Jaggi, Rolf
Publicado 2008

Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue

por Antonov, Janine, Popovici, Vlad, Delorenzi, Mauro, Wirapati, Pratyaksha, Baltzer, Anna, Oberli, Andrea, Thürlimann, Beat, Giobbie-Hurder, Anita, Viale, Giuseppe, Altermatt, Hans Jörg, Aebi, Stefan, Jaggi, Rolf
Publicado 2010

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

por Zander, Thilo, Pabst, Thomas, Schär, Sämi, Aebi, Stefan, Mey, Ulrich, Novak, Urban, Lerch, Erika, Rhyner Agocs, Gaëlle, Goede, Jeroen, Maniecka, Zuzanna, Hayoz, Stefanie, Rüfer, Axel, Renner, Christoph, Driessen, Christoph
Publicado 2023

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

por Schmid, Sabine, Klingbiel, Dirk, Aebi, Stefan, Goldhirsch, Aron, Mamot, Christoph, Munzone, Elisabetta, Nolè, Franco, Oehlschlegel, Christian, Pagani, Olivia, Pestalozzi, Bernhard, Rochlitz, Christoph, Thürlimann, Beat, von Moos, Roger, Weder, Patrik, Zaman, Khalil, Ruhstaller, Thomas
Publicado 2019

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

por Pestalozzi, Bernhard C., Tausch, Christoph, Dedes, Konstantin J., Rochlitz, Christoph, Zimmermann, Stefan, von Moos, Roger, Winterhalder, Ralph, Ruhstaller, Thomas, Mueller, Andreas, Buser, Katharina, Borner, Markus, Novak, Urban, Nussbaum, Catrina Uhlmann, Seifert, Bettina, Bigler, Martin, Bize, Vincent, Vilei, Simona Berardi, Rageth, Christoph, Aebi, Stefan
Publicado 2017

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

por Ribi, Karin, Luo, Weixiu, Colleoni, Marco, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L., Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg
Publicado 2019

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

por Ribi, Karin, Luo, Weixiu, Colleoni, Marco, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L., Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg
Publicado 2020

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

por Bayani, Jane, Poncet, Coralie, Crozier, Cheryl, Neven, Anouk, Piper, Tammy, Cunningham, Carrie, Sobol, Monika, Aebi, Stefan, Benstead, Kim, Bogler, Oliver, Dal Lago, Lissandra, Fraser, Judith, Hilbers, Florentine, Hedenfalk, Ingrid, Korde, Larissa, Linderholm, Barbro, Martens, John, Middleton, Lavinia, Murray, Melissa, Kelly, Catherine, Nilsson, Cecilia, Nowaczyk, Monika, Peeters, Stephanie, Peric, Aleksandra, Porter, Peggy, Schröder, Carolien, Rubio, Isabel T., Ruddy, Kathryn J., van Asperen, Christi, Van Den Weyngaert, Danielle, van Deurzen, Carolien, van Leeuwen-Stok, Elise, Vermeij, Joanna, Winer, Eric, Giordano, Sharon H., Cardoso, Fatima, Bartlett, John M. S.
Publicado 2021